Raymond James & Associates’s Axcelis ACLS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACLS
SM
RP
Raymond James & Associates's ACLS Position: Q3 2024 in Review
Raymond James & Associates sold out of Axcelis (ACLS) in Q3 2024, closing a stake of 1,778 shares — an estimated $253K sold.
Raymond James & Associates first reported a position in ACLS in Q4 2017 and held it in 16 quarters. The position peaked at $3.13M in Q2 2023. 368 funds tracked by Wall St. Rank hold ACLS as of Q3 2024.
- Raymond James & Associates reported no remaining Axcelis position as of Q3 2024 after selling out during the quarter.
- Raymond James & Associates sold 1,778 Axcelis shares in Q3 2024, an estimated $253K.
- Raymond James & Associates first reported a position in Axcelis in Q4 2017 and held it in 16 quarters.
- Raymond James & Associates's Axcelis position peaked at $3.13M in Q2 2023.
- 368 funds tracked by Wall St. Rank held Axcelis as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.